Blocking Hemopexin With Specific Antibodies: A New Strategy for Treating Diabetic Retinopathy
Diabetes · 2023
DOI: 10.2337/db23-0027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Patricia Bogdanov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus, Experimental. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Hemopexin (HPX) is overexpressed in the retina of patients with diabetes and induces the breakdown of the blood-retinal barrier in vitro. The aim of this study was to evaluate whether HPX blockade by specific antibodies (aHPX) could avoid vascular leakage in vivo and microvascular angiogenesis in vitro and ex vivo. For this purpose, the effect of intravitreal (IVT) injections of aHPX on vascular leakage was evaluated in db/db mice and rats with streptozotocin-induced diabetes using the Evans Blue method. Retinal neurodegeneration and inflammation were also evaluated. The antiangiogenic effect of aHPX on human retinal endothelial cells (HRECs) was tested by scratch wound healing and tube formation using standardized methods, as well as by choroidal sprouting assays from retinal explants obtained in rats. We found that IVT injection of aHPX significantly reduced vascular leakage, retinal neurodegeneration, and inflammation. In addition, treatment with aHPX significantly reduced HREC migration and tube formation induced by high glucose concentration and suppressed choroidal sprouting even after vascular endothelial growth factor stimulation, with this effect being higher than obtained with bevacizumab. The antipermeability and antiangiogenic effects of IVT injection of aHPX suggest the blockade or inhibition of HPX as a new strategy for the treatment of advanced stages of diabetic retinopathy. Article Highlights Hemopexin (HPX) is the best-characterized permeability factor in steroid-sensitive nephrotic syndrome. We have previously reported that HPX is overexpressed in the retina of patients with diabetes and induces the breakdown of the blood-retinal barrier in vitro. Here, we report that intravitreal injection of anti-HPX antibodies significantly reduces vascular leakage, retinal neurodegeneration, and inflammation in diabetic murine models and that the immunoneutralization of HPX exerts a significant antiangiogenic effect in vitro and in retinal explants. The blockade of HPX can be considered as a new therapy for advanced stages of diabetic retinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.
- Ophthalmology Research Group, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
- Unit of High Technology, Vall d'Hebron Research Institute, Barcelona, Spain.
ORCID-Profile: Rafael Simó, Cristina Hernández
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Bogdanov, P., Duarri, A., Sabater, D., Salas, A., Isla-Magrané, H., Ramos, H., Huerta, J., Valeri, M., García-Arumí, J., Simó, R., & Hernández, C. (2023). Blocking Hemopexin With Specific Antibodies: A New Strategy for Treating Diabetic Retinopathy. Diabetes. https://doi.org/10.2337/db23-0027
Vancouver
Bogdanov P, Duarri A, Sabater D, Salas A, Isla-Magrané H, Ramos H, et al. Blocking Hemopexin With Specific Antibodies: A New Strategy for Treating Diabetic Retinopathy. Diabetes. 2023. doi:10.2337/db23-0027
BibTeX
@article{Bogdanov2023,
author = {Bogdanov, Patricia and Duarri, Anna and Sabater, David and Salas, Anna and Isla-Magrané, Helena and Ramos, Hugo and Huerta, Jordi and Valeri, Marta and García-Arumí, José and Simó, Rafael and Hernández, Cristina},
title = {Blocking Hemopexin With Specific Antibodies: A New Strategy for Treating Diabetic Retinopathy},
journal = {Diabetes},
year = {2023},
doi = {10.2337/db23-0027}
}
EUVIMED